9 March 2022
The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford. In the first study of its kind, after vaccination volunteers will be ‘challenged’ with paratyphoid to see whether the vaccine can prevent infection.
The Vaccine Against Salmonella Paratyphi (VASP) study will assess the immune response, efficacy and safety of a new vaccine, CVD 1902, against paratyphoid fever (a form of enteric fever similar to typhoid), which is given by mouth as a drink. CVD 1902 was developed by a team of scientists at the Center for Vaccine Development and Global Health (CVD) of the UMSoM. The use of a human challenge model to do this will allow an understanding of the vaccine’s effectiveness without having to immunise thousands of people.
A planned sample of up to 76 participants – aged 18 to 55 and in good health – will be randomised to either receive two doses of the new paratyphoid vaccine or a placebo given 14 days apart. All participants will then be challenged with paratyphoid bacteria to see if they are protected against infection.
Following challenge, participants will be monitored closely and treated with antibiotics as soon as they show signs of infection, or after two weeks if they do not show any signs of infection. Results are expected in 2023.
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the trial, said:
‘Vaccines are urgently needed to prevent the 3.3 million cases of paratyphoid fever that mostly affects school-age children in South and South East Asia. This first human challenge study to evaluate a paratyphoid vaccine will bring us a step closer to reducing the burden of this affliction in the world.’
Professor Brian Angus, Director of the Oxford Centre for Clinical Tropical Medicine and Global Health and Principal Investigator of the trial, said:
'Enteric fever is a common infectious disease worldwide spread by drinking contaminated water. Although mainly caused by Salmonella Typhi a quarter of cases are due to another organism Salmonella Paratyphi. A new vaccine has recently been approved for typhoid, but no vaccine currently is licensed for paratyphoid. Due to increasing antibiotic resistance, the need for vaccines against these bacteria are desperately needed.'
Dr Maheshi Ramasamy, Senior Clinical Researcher and Principal Investigator of the trial, said:
'Here in Oxford, we have developed safe, controlled ways of studying malaria, typhoid and COVID-19 infections in volunteers.
'Building on this experience, we will be using a human model of paratyphoid infection to study the efficacy of a new vaccine against this disease which disproportionately affects low and middle income countries.'
Myron (Mike) M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor of Medicine and Associate Dean for Global Health, Vaccinology and Infectious Diseases, who led the team at the UMSoM that developed the CVD 1902 vaccine, said:
‘An oral vaccine is easy to administer and can stimulate ‘local’ protective immune responses along the surface of the intestine, as well as systemic immunity. For more than a decade, the CVD and the Oxford Vaccine Group have worked together on projects to find improved ways to prevent typhoid and paratyphoid fevers.’
Volunteers interested in enrolling on the study can do so online at https://trials.ovg.ox.ac.uk/trials/vasp
Notes for editors
For further information or to request an interview with the researchers, please contact: firstname.lastname@example.org or call 01865 280528.
Trial link – https://trials.ovg.ox.ac.uk/trials/vasp
YouTube link – https://www.youtube.com/watch?v=53DZdITzDuI
About Salmonella Paratyphi A
Salmonella Paratyphi A is a bacterium that can cause a disease called enteric (paratyphoid) fever. Although it is from the same family as the Salmonella bacteria that cause gastroenteritis in the UK, it is quite different. Paratyphoid infection is most common in resource-poor communities in Asia with inadequate sanitation and limited access to safe water.
The bacteria are spread when infected individuals' faeces contaminate food and water sources. Symptoms of infection include headache, fever, chills and general aches and pains. If not treated properly paratyphoid infection can lead to severe complications and even death.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the sixth year running, and 2 in the QS World Rankings 2022. At the heart of this success is our ground-breaking research and innovation.
Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs.